JP6383665B2 - ＩＬ‐１β中和ヒトモノクローナル抗体 - Google Patents

ＩＬ‐１β中和ヒトモノクローナル抗体 Download PDF

Info

Publication number
JP6383665B2
JP6383665B2 JP2014557603A JP2014557603A JP6383665B2 JP 6383665 B2 JP6383665 B2 JP 6383665B2 JP 2014557603 A JP2014557603 A JP 2014557603A JP 2014557603 A JP2014557603 A JP 2014557603A JP 6383665 B2 JP6383665 B2 JP 6383665B2
Authority
JP
Japan
Prior art keywords
isolated
antibody
agent
specific antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014557603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518368A5 (cg-RX-API-DMAC7.html
JP2015518368A (ja
Inventor
ワン，チュンイ
ゴー，アンジェリーン
エオ，シオピン
モルテラーロ，アレッサンドラ
クマール ビスワス，サブラ
クマール ビスワス，サブラ
ジンウ，フローレント
ジョン，ピンユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2015518368A publication Critical patent/JP2015518368A/ja
Publication of JP2015518368A5 publication Critical patent/JP2015518368A5/ja
Application granted granted Critical
Publication of JP6383665B2 publication Critical patent/JP6383665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014557603A 2012-02-13 2013-02-13 ＩＬ‐１β中和ヒトモノクローナル抗体 Active JP6383665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG201201007-0 2012-02-13
SG2012010070 2012-02-13
PCT/SG2013/000057 WO2013122544A2 (en) 2012-02-13 2013-02-13 IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2015518368A JP2015518368A (ja) 2015-07-02
JP2015518368A5 JP2015518368A5 (cg-RX-API-DMAC7.html) 2016-03-31
JP6383665B2 true JP6383665B2 (ja) 2018-08-29

Family

ID=54261183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557603A Active JP6383665B2 (ja) 2012-02-13 2013-02-13 ＩＬ‐１β中和ヒトモノクローナル抗体

Country Status (17)

Country Link
US (5) US10167335B2 (cg-RX-API-DMAC7.html)
EP (2) EP2814843B1 (cg-RX-API-DMAC7.html)
JP (1) JP6383665B2 (cg-RX-API-DMAC7.html)
CN (1) CN105431452B (cg-RX-API-DMAC7.html)
CY (1) CY1123519T1 (cg-RX-API-DMAC7.html)
DK (1) DK2814843T3 (cg-RX-API-DMAC7.html)
ES (1) ES2798110T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200964T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049860T2 (cg-RX-API-DMAC7.html)
LT (1) LT2814843T (cg-RX-API-DMAC7.html)
PL (1) PL2814843T3 (cg-RX-API-DMAC7.html)
PT (1) PT2814843T (cg-RX-API-DMAC7.html)
RS (1) RS60583B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201404850SA (cg-RX-API-DMAC7.html)
SI (1) SI2814843T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000321T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013122544A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6383665B2 (ja) 2012-02-13 2018-08-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ＩＬ‐１β中和ヒトモノクローナル抗体
CN106928354B (zh) * 2017-04-25 2020-07-17 长春金赛药业有限责任公司 抗IL-1β单克隆抗体及其应用
TW201904993A (zh) * 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
CN115028723B (zh) * 2019-03-07 2023-08-29 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
KR102087743B1 (ko) * 2019-06-10 2020-03-12 을지대학교 산학협력단 IL-1beta에 특이적으로 결합하는 항체 및 그의 용도
WO2025006936A2 (en) * 2023-06-29 2025-01-02 University Of Maine System Board Of Trustees Methods and compositions for fire-fighting
WO2025147459A1 (en) 2024-01-04 2025-07-10 Nano Precision Medical, Inc. Stabilization of peptides and proteins in implantable devices and formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE195003T1 (de) 1994-07-05 2000-08-15 Steeno Res Group As Immunomodulatoren
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030007972A1 (en) 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
CA2509136C (en) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2488201A4 (en) 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
WO2012121679A1 (en) 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6383665B2 (ja) 2012-02-13 2018-08-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ＩＬ‐１β中和ヒトモノクローナル抗体
WO2016008851A1 (en) 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
JP6941565B2 (ja) 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US10397741B2 (en) 2016-11-11 2019-08-27 Shoreline Tracking Systems, LLC System and method for service tracking
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof

Also Published As

Publication number Publication date
WO2013122544A2 (en) 2013-08-22
RS60583B1 (sr) 2020-08-31
EP2814843A4 (en) 2016-04-06
CN105431452A (zh) 2016-03-23
US20190144535A1 (en) 2019-05-16
ES2798110T3 (es) 2020-12-09
SMT202000321T1 (it) 2020-07-08
US11702471B2 (en) 2023-07-18
US10167335B2 (en) 2019-01-01
US10919962B2 (en) 2021-02-16
US20210155686A1 (en) 2021-05-27
US20210024627A1 (en) 2021-01-28
EP3736289A1 (en) 2020-11-11
SG11201404850SA (en) 2014-09-26
US20210155685A1 (en) 2021-05-27
PT2814843T (pt) 2020-06-18
SG10201708562VA (en) 2017-12-28
PL2814843T3 (pl) 2020-11-16
EP2814843B1 (en) 2020-03-18
EP2814843A2 (en) 2014-12-24
LT2814843T (lt) 2020-09-25
HUE049860T2 (hu) 2020-11-30
CY1123519T1 (el) 2022-03-24
WO2013122544A9 (en) 2014-10-02
US20150037248A1 (en) 2015-02-05
WO2013122544A3 (en) 2015-03-26
US11912761B2 (en) 2024-02-27
SI2814843T1 (sl) 2020-11-30
US11780913B2 (en) 2023-10-10
JP2015518368A (ja) 2015-07-02
DK2814843T3 (da) 2020-06-22
CN105431452B (zh) 2019-12-31
HRP20200964T1 (hr) 2020-10-30

Similar Documents

Publication Publication Date Title
US11702471B2 (en) IL-1β neutralizing human monoclonal antibodies
US10479830B2 (en) Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
JP7037940B2 (ja) 特発性肺線維症の治療方法
CN115975027B (zh) Il-11人源化抗体及其应用
CN105358175B (zh) 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
MX2014004662A (es) Antagonistas de il17c para el tratamiento de trastornos inlflamatorios.
CA3114295A1 (en) Il-36 antibodies and uses thereof
CN114786722A (zh) 抗类趋化因子受体1人源化抗体及其治疗应用
CA3235627A1 (en) Anti-activin a antibodies, compositions and uses thereof
CN116322713A (zh) 使用抗组织因子抗体进行炎性疾病治疗
CA3124356A1 (en) Fn14 antibodies and uses thereof
KR20190126829A (ko) 간 질환을 치료하는데 사용하기 위한 항-ccl24(에오탁신 2) 항체
HK40041071A (en) Il-beta neutralizing human monoclonal antibodies
RU2852383C1 (ru) Бифункциональный слитый белок и его применение
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
WO2025051889A1 (en) Anti pd-l2 antibodies for use in treating fibrotic diseases
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180419

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180806

R150 Certificate of patent or registration of utility model

Ref document number: 6383665

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250